What one share of Emmaus Life Sciences holds
We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription grade L-glutamine oral powder) is approved by the U.S.
Emmaus Life Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.23 |
|---|---|
| Profit | −$0.09 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.06 |
| Cash and investments | $0.04 |
| Debt | $0.36 |
| Book value | −$0.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2015 | — | −$6.64 | — | — | — | −$9.44 |
| 2016 | — | −$9.26 | $0.01 | −$4.65 | — | — |
| 2017 | $0.05 | −$2.52 | $0.05 | −$1.75 | — | $1.06 |
| 2018 | $0.25 | −$1.86 | $0.01 | −$1.75 | — | $0.54 |
| 2018 | $0.45 | −$1.97 | $0.00 | −$0.16 | — | −$0.58 |
| 2019 | $0.54 | −$1.30 | $0.00 | −$0.11 | — | −$0.23 |
| 2021 | $0.42 | −$0.32 | $0.00 | −$0.03 | — | −$0.43 |
| 2022 | $0.37 | −$0.21 | $0.00 | −$0.10 | — | −$0.69 |
| 2023 | $0.56 | −$0.07 | $0.00 | −$0.03 | — | −$0.77 |
| 2024 | $0.26 | −$0.10 | $0.00 | −$0.04 | — | −$0.88 |
| 2025 | $0.19 | −$0.12 | $0.00 | −$0.00 | — | −$0.91 |
Common questions about Emmaus Life Sciences
How much does one share of Emmaus Life Sciences earn?
Over the last 12 months, Emmaus Life Sciences lost $0.09 for each share on $0.23 of sales.
Does Emmaus Life Sciences pay a dividend?
Emmaus Life Sciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Emmaus Life Sciences’s book value per share?
Emmaus Life Sciences’s book value is negative (−$0.94 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Emmaus Life Sciences have?
Each share of Emmaus Life Sciences has $0.04 of cash and investments and $0.36 of debt, as of June 30, 2026.
What is Emmaus Life Sciences’s free cash flow per share?
$0.06 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Emmaus Life Sciences bought back shares?
Emmaus Life Sciences’s share count rose about 12480% from 2015 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.